disease models. These efforts received a boost with the success of ABL kinase 23 inhibitor, Imatinib (also known as Gleevec or STI571), the first kinase targeted therapy 24 in chronic myeloid leukemia (CML). Though Imatinib was not curative in CML; the long 25 term survival of CML patients is now similar to that of age matched population. 1 Imatinib
26
was not as successful in other malignancies driven by its target kinases but it provided 27 the impetus for expanding the repertoire of kinase targeted therapies in oncology. In a cancer are being applied to disorders involving immune cell hyperactivation (Table 1) 35 and more recently for selective reactivation of immune cell function. 
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Phosphatidylinositol 3-kinase delta blockade increases genomic instability in B cells. 
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT

